View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Modern Renters Crave Easy, Digital Experiences, AppFolio Research Find...

Modern Renters Crave Easy, Digital Experiences, AppFolio Research Finds Report reveals growing appetite for services that deliver convenience Property managers must elevate the resident experience to attract renters amid rising competition SANTA BARBARA, Calif., May 22, 2025 (GLOBE NEWSWIRE) --   (NASDAQ:APPF), the technology leader powering the future of the real estate industry, today released its . Drawing on insights from over 2,000 U.S. renters, the report outlines key strategies for property managers to gain an edge in a shaped by rising costs, higher vacancies, and slower rent g...

Appfolio Inc: 2 directors

Two Directors at Appfolio Inc sold 6,957 shares at between 211.450USD and 221.130USD. The significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...

 PRESS RELEASE

OPKO Health to Participate in Two Upcoming Investor Conferences

OPKO Health to Participate in Two Upcoming Investor Conferences MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in two investor conferences over the coming weeks. H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City. Management will hold one-on-one meetings with investors and will participate in a fireside discussion at 9:00 a.m. Eastern time. Jefferies Global Healthcare Conference, June 3-5 at the Marriott Marquis in New York City. Management will hold one-on-one meet...

 PRESS RELEASE

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 183,885 shares of the Company’s common stock to seven new employees (the “Inducement G...

 PRESS RELEASE

89bio to Participate in Upcoming Investor Conferences

89bio to Participate in Upcoming Investor Conferences SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in the following investor conferences during the month of May: BofA Securities 2025 Health Care ConferenceFormat: Fireside ChatDate: Wednesday, May 14, 2025Time: 1:40 PM ET 2025 RBC Capital Markets Gl...

 PRESS RELEASE

89bio Reports First Quarter 2025 Financial Results and Corporate Updat...

89bio Reports First Quarter 2025 Financial Results and Corporate Updates – Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) has been fully enrolled and topline data are expected in 1Q 2026 – – Cash, cash equivalents, and marketable securities totaled $638.8 million as of March 31, 2025; completed...

 PRESS RELEASE

OPKO Health Reports First Quarter 2025 Business Highlights and Financi...

OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2025. Highlights from the first quarter of 2025 and recent weeks include the following: Signed definitive agreement with Labcorp to sell oncology and related clinical testing assets of BioReference Health (BioReference). The transaction includes the sale of BioReference’s laboratory te...

 PRESS RELEASE

AppFolio, Inc. Announces First Quarter 2025 Financial Results

AppFolio, Inc. Announces First Quarter 2025 Financial Results Strong New Business in the First Quarter and Investment to Accelerate the Resident Experience SANTA BARBARA, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- AppFolio, Inc. (NASDAQ: APPF) ("AppFolio" or the "Company"), a technology leader powering the future of the real estate industry, today announced its financial results for the first quarter ended March 31, 2025. “AppFolio’s first quarter results underscore that our ongoing commitment to delivering industry-leading innovation and exceptional service is driving new customer ado...

 PRESS RELEASE

AppFolio and Second Nature Announce Partnership to Enhance the Residen...

AppFolio and Second Nature Announce Partnership to Enhance the Resident Experience New offering delivers convenience and benefits to residents while solving compliance and operational challenges for property managers SANTA BARBARA, CA and RALEIGH, N.C., April 17, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:APPF), a technology leader powering the future of the real estate industry, and , a proptech company and leader in the resident experience, today announced a strategic partnership to enhance the resident experience for the millions of residents their customers serve. Through this partnership...

 PRESS RELEASE

OPKO Health to Report First Quarter 2025 Financial Results on April 30...

OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025 MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Wednesday, April 30, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 30th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to p...

 PRESS RELEASE

AppFolio, Inc. Announces Date of First Quarter 2025 Financial Results ...

AppFolio, Inc. Announces Date of First Quarter 2025 Financial Results Conference Call SANTA BARBARA, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- AppFolio, Inc. (NASDAQ: APPF) today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, April 24, 2025. In conjunction with this announcement, AppFolio will host a conference call on Thursday, April 24, 2025, at 5:00 p.m. (Eastern Time), to discuss the company’s financial results and business outlook. A live webcast of the call will be available at . To access the call ...

 PRESS RELEASE

OPKO Health Announces $100 Million Increase to its Existing Share Repu...

OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the Company’s existing common stock repurchase program, bringing the aggregate capacity of the program to $200 million. Approximately $41 million of OPKO’s common stock has been repurchased under the existing program since its authorization in July 2024. “We believe OPKO’s shares continue to be significantly undervalued and offer an attractive...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: April 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: April 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: March 28, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 22, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Opko Health Inc: 1 director

A director at Opko Health Inc bought 200,000 shares at 1.739USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch